Gossamer Bio

Gossamer Bio Financial Debt Ratio

The Financial Debt Ratio of Gossamer Bio (GOSS) as of Oct 17, 2026 is 117.80 %. In the previous year, Financial Debt Ratio was 64.35 % — a change of 83.07% (higher).

Financial Debt Ratio

117.80 %

YoY

83.07%

Last updated:

Financial Debt Ratio of Gossamer Bio is 2025 117.80 % . Financial Debt Ratio of Gossamer Bio was 2024 64.35 % . It decreases by 83.07% higher compared to the previous year.

The Gossamer Bio Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2017
1,357.30 USD
Jan 1, 2019
9.27 USD
Jan 1, 2020
34.06 USD
Jan 1, 2021
53.90 USD
Jan 1, 2022
82.86 USD
Jan 1, 2023
68.12 USD
Jan 1, 2024
64.35 USD
Jan 1, 2025
117.80 USD
The Gossamer Bio Financial Debt Ratio history
YEARFinancial Debt RatioYoY
117.80 %+83.07%
64.35 %-5.53%
68.12 %-17.79%
82.86 %+53.72%
53.90 %+58.25%
34.06 %+267.39%
9.27 %-99.32%
1,357.30 %+1,935.96%
66.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Gossamer Bio Stock analysis

What does Gossamer Bio do? The company Gossamer Bio Inc. was founded in 2015 by Faheem Hasnain and Sheila Gujrathi. The founders had previously worked at various biotechnology companies and now wanted to start their own company to develop innovative products in the field of immunology. Gossamer Bio is headquartered in San Diego, California and currently employs around 200 people. The company specializes in researching and developing therapeutics for a wide range of diseases, including respiratory diseases, cancer, immunological disorders, and infections. Gossamer Bio's business model is based on identifying promising new drug candidates and subsequently developing therapeutics that have the potential to improve patients' lives. Key pillars of the business model include partnerships with established companies and investors, as well as the rapid and efficient conduct of clinical trials. Gossamer Bio's portfolio includes various pipeline programs in different stages of development. An important focus is on the development of new drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A promising drug candidate in this area is GB001, an inhalation medication that aims to reduce inflammation in the airways. Another important program of Gossamer Bio is the development of therapeutics for the treatment of cancer. The company focuses on the development of drugs that target the body's immune system to specifically fight tumor cells. A promising drug candidate in this area is GB1275, an antibody that specifically targets a protein overexpressed by some types of cancer. In addition to these two focus areas, Gossamer Bio also has programs in the development of therapeutics for the treatment of immunological disorders such as inflammatory bowel disease and rheumatoid arthritis, as well as for the treatment of infections such as COVID-19. Overall, Gossamer Bio has a wide range of promising drug candidates that have the potential to revolutionize the field of immunology and disease management. The company is well positioned to make significant progress in the development of new therapeutics in the coming years and improve the lives of millions of patients worldwide. Gossamer Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gossamer Bio stock

Financial Debt Ratio of Gossamer Bio is 117.80 % in 2025.

Financial Debt Ratio of Gossamer Bio changed from 64.35 % to 117.80 %, representing a 83.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Gossamer Bio since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Gossamer Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Gossamer Bio

All Key Metrics — Gossamer Bio